Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome

Bone Marrow Transplantation

Volumn 38, Issue 1, 2006, Pages 17-21

  Cox Brinkman, J ^a   Boelens, J J ^b   Wraith, J E ^c   O'Meara, A ^d   Veys, P ^e   Wijburg, F A ^a   Wulffraat, N ^b   Wynn, R F ^c  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Alpha L iduronidase; Enzyme replacement therapy; Haematopoietic cell transplantation; Mucopolysaccharidosis type 1

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; LARONIDASE; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; CELL TRANSPLANTATION; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DONOR; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME REPLACEMENT; HEMATOPOIETIC CELL; HUMAN; HUNTER SYNDROME; LYMPHOCYTE TRANSFUSION; MORBIDITY; PRIORITY JOURNAL; SURVIVAL; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDURONIDASE; INFANT; MUCOPOLYSACCHARIDOSIS I; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33745257246     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705401     Document Type: Article

References (19)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic & molecular bases of inherited disease. McGraw-Hill: New York, 2001, pp 3421-3452.
2. Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981; 2: 709-712.
3. Braunlin EA, Stauffer NR, Peters CH, Bass JL, Berry JM, Hopwood JJ et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 2003; 92: 882-886.
4. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 2003; 31: 1105-1117.
5. Vellodi A, Young EP, Cooper A, Wraith JE, Winchester B, Meaney C et al. Bone marrow transplantation for mucopolysaccharidosis type I: Experience of two British centres. Arch Dis Childhood 1997; 76: 92-99.
6. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87: 4894-4902.
7. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ et al. Hurler syndrome: II. Outcome of HLA genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998; 91: 2601-2608.
8. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350: 1960-1969.
9. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182-188.
10. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J et al. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (Laronidase). J Pediatr 2004; 144: 581-588.
11. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in a canine model of Hurler-syndrome. Proc Natl Acad Sci USA 1994; 91: 12937-12941.
12. Baxter MA, Wynn RF, Schyma L, Holmes DK, Wraith JE, Fairbairn LJ et al. Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development. J Inherit Metab Dis 2005; 28: 1045-1053.
13. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer 1987; 60: 1651-1656.
14. Boelens JJ, Wynn R, O'Mearra A, Veys P, Cavazzana-Calzo M, Wulffraat N. Results of haematopoietic stem cell transplantation (HSCT) for Hurler's syndrome: European experience 1994-2004. Blood 2005; 106: 121a (abstr. 402).
15. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993; 81: 1679-1690.
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
18. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746-750.
19. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 2005; 7: 143-146.